Non-progressive breast carcinomas detected at mammography screening: a population study.

Torunn Heggland, Lars Johan Vatten, Signe Opdahl, Harald Weedon-Fekjær
{"title":"Non-progressive breast carcinomas detected at mammography screening: a population study.","authors":"Torunn Heggland,&nbsp;Lars Johan Vatten,&nbsp;Signe Opdahl,&nbsp;Harald Weedon-Fekjær","doi":"10.1186/s13058-023-01682-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Some breast carcinomas detected at screening, especially ductal carcinoma in situ, may have limited potential for progression to symptomatic disease. To determine non-progression is a challenge, but if all screening-detected breast tumors eventually reach a clinical stage, the cumulative incidence at a reasonably high age would be similar for women with or without screening, conditional on the women being alive.</p><p><strong>Methods: </strong>Using high-quality population data with 24 years of follow-up from the gradually introduced BreastScreen Norway program, we studied whether all breast carcinomas detected at mammography screening 50-69 years of age would progress to clinical symptoms within 85 years of age. First, we estimated the incidence rates of breast carcinomas by age in scenarios with or without screening, based on an extended age-period-cohort incidence model. Next, we estimated the frequency of non-progressive tumors among screening-detected cases, by calculating the difference in the cumulative rate of breast carcinomas between the screening and non-screening scenarios at 85 years of age.</p><p><strong>Results: </strong>Among women who attended BreastScreen Norway from the age of 50 to 69 years, we estimated that 1.1% of the participants were diagnosed with a breast carcinoma without the potential to progress to symptomatic disease by 85 years of age. This proportion of potentially non-progressive tumors corresponded to 15.7% [95% CI 3.3, 27.1] of breast carcinomas detected at screening.</p><p><strong>Conclusions: </strong>Our findings suggest that nearly one in six breast carcinomas detected at screening may be non-progressive.</p>","PeriodicalId":9283,"journal":{"name":"Breast Cancer Research : BCR","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318793/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research : BCR","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13058-023-01682-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Some breast carcinomas detected at screening, especially ductal carcinoma in situ, may have limited potential for progression to symptomatic disease. To determine non-progression is a challenge, but if all screening-detected breast tumors eventually reach a clinical stage, the cumulative incidence at a reasonably high age would be similar for women with or without screening, conditional on the women being alive.

Methods: Using high-quality population data with 24 years of follow-up from the gradually introduced BreastScreen Norway program, we studied whether all breast carcinomas detected at mammography screening 50-69 years of age would progress to clinical symptoms within 85 years of age. First, we estimated the incidence rates of breast carcinomas by age in scenarios with or without screening, based on an extended age-period-cohort incidence model. Next, we estimated the frequency of non-progressive tumors among screening-detected cases, by calculating the difference in the cumulative rate of breast carcinomas between the screening and non-screening scenarios at 85 years of age.

Results: Among women who attended BreastScreen Norway from the age of 50 to 69 years, we estimated that 1.1% of the participants were diagnosed with a breast carcinoma without the potential to progress to symptomatic disease by 85 years of age. This proportion of potentially non-progressive tumors corresponded to 15.7% [95% CI 3.3, 27.1] of breast carcinomas detected at screening.

Conclusions: Our findings suggest that nearly one in six breast carcinomas detected at screening may be non-progressive.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺钼靶筛查发现的非进行性乳腺癌:一项人群研究。
背景:筛查中发现的一些乳腺癌,尤其是导管原位癌,可能进展为症状性疾病的可能性有限。确定非进展是一个挑战,但如果所有筛查发现的乳腺肿瘤最终都达到临床阶段,那么无论是否进行筛查的女性,在合理的高年龄段的累积发病率都是相似的,这取决于女性是否活着。方法:利用逐步引入的挪威乳腺筛查项目24年随访的高质量人群数据,我们研究了50-69岁乳腺钼靶筛查中检测到的所有乳腺癌是否会在85岁内发展为临床症状。首先,我们根据延长年龄段队列发病率模型,估计了在有或没有筛查的情况下,按年龄划分的乳腺癌发病率。接下来,我们通过计算85岁时筛查和非筛查情况下乳腺癌累积发病率的差异,估计了筛查发现病例中非进行性肿瘤的发生频率。结果:在50岁至69岁参加挪威乳腺筛查的女性中,我们估计1.1%的参与者在85岁时被诊断为乳腺癌,而没有发展为症状性疾病的可能性。这一比例的潜在非进行性肿瘤对应于筛查中检测到的15.7%[95%CI 3.327.1]的乳腺癌。结论:我们的研究结果表明,在筛查中发现的乳腺癌中,近六分之一可能是非进展性的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression. Quantitative characterization of breast lesions and normal fibroglandular tissue using compartmentalized diffusion-weighted model: comparison of intravoxel incoherent motion and restriction spectrum imaging AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A hypusination-TCF4 axis NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer Receptor conversion and survival in breast cancer liver metastases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1